News
Novo Nordisk has launched a new late-stage trial for its experimental next-generation obesity drug candidate, CagriSema, as ...
Key Takeaways Novo Nordisk stock rose on Tuesday after the Financial Times reported that an activist investor is building a ...
Activist hedge fund Parvus Asset Management is building a stake in Novo Nordisk , after the company lost its first mover ...
A media report stated that an activist investor is accumulating a stake in the Wegovy maker. Wegovy and Ozempic maker Novo ...
Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...
Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...
Early-stage study results suggest that a single shot of the company’s therapy, which works differently than GLP-1 medicines, ...
Novo Nordisk slashed its spending on TV ads for Wegovy by almost 24% between April and May, from $31.6 million to $24.1 ...
STARING at yet another pregnancy test, Erica Coronado was thrilled but terrified. The 36-year-old had given up hope of a baby ...
WEIGHT loss jabs could prevent a medication taken by millions of women from working – and increase patients’ risk of cancer. The British Menopause Society said the jabs could cause ...
26m
24/7 Wall St. on MSNBought $40,000 of Hims & Hers (HIMS) Stock on a YOLO - Is it Time to Sell?Hims & Hers (NYSE: HIMS) stock, a prominent player in the booming telehealth sector, has undeniably captured significant investor attention recently. Perhaps you, like many others, have been caught up ...
CVS Caremark identified GLP-1 drugs and Humira as points of contention, but the State Health Plan says that mischaracterizes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results